normally appears not to affect the diabetic control
of most patients taking sulphonylureas, but isolated reports describe hypoglycaemic coma and aggressive behaviour following concurrent use. Fluconazole
may cause marked increases in plasma
levels of glimepiride
, but the significance of this is unclear. Nateglinide plasma
levels may also be increased by fluconazole
, but this did not affect the control
of blood glucose levels.
There is no reason to avoid concurrent use but warn patients to report any unexpected changes in blood glucose levels.